| Ident. | Authors (with country if any) | Title |
|---|
| 000031 (2021) |
Hülya Gamze Çelik [Turquie] ; Iran Keske [Turquie] ; Ülker Ener [Turquie] ; Müge Tekba [Turquie] ; Mahir Kapmaz [Turquie] ; Krü Taylan Ahin [Turquie] ; Asl Özy Ld R M [Turquie] ; Saide Aytekin [Turquie] ; Vedat Aytekin [Turquie] ; Önder Ergönül [Turquie] | Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic? |
| 000079 (2021) |
Nicolas Dauby [Belgique] ; Emmanuel Bottieau [Belgique] | The unfinished story of hydroxychloroquine in COVID-19: The right anti-inflammatory dose at the right moment? |
| 000196 (2021) |
A J J. Lammers [Pays-Bas] ; R M Brohet [Pays-Bas] ; R E P. Theunissen [Pays-Bas] ; C. Koster [Pays-Bas] ; R. Rood [Pays-Bas] ; D W M. Verhagen [Pays-Bas] ; K. Brinkman [Pays-Bas] ; R J Hassing [Pays-Bas] ; A. Dofferhoff [Pays-Bas] ; R. El Moussaoui [Pays-Bas] ; G. Hermanides [Pays-Bas] ; J. Ellerbroek [Pays-Bas] ; N. Bokhizzou [Pays-Bas] ; H. Visser [Pays-Bas] ; M. Van Den Berge [Pays-Bas] ; H. Bax [Pays-Bas] ; D F Postma [Pays-Bas] ; P H P. Groeneveld [Pays-Bas] | Response to correspondence concerning: "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients". |
| 000200 (2021) |
Marijke Linschoten [Pays-Bas] ; Linda Nab [Pays-Bas] ; Iwan C C. Van Der Horst [Pays-Bas] ; Robert Tieleman [Pays-Bas] ; Folkert W. Asselbergs [Royaume-Uni] | Response to "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients". |
| 000230 (2021) |
Faryal Khamis [Oman] ; Hanan Al Naabi [Oman] ; Adil Al Lawati [Oman] ; Zaiyana Ambusaidi [Oman] ; Mariam Al Sharji [Oman] ; Umkulthum Al Barwani [Oman] ; Nenad Pandak [Oman] ; Zakariya Al Balushi [Oman] ; Maher Al Bahrani [Oman] ; Issa Al Salmi [Oman] ; Ibrahim Al-Zakwani [Oman] | Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. |
| 000258 (2021) |
Gagan Kumar [États-Unis] ; Alex Adams [États-Unis] ; Martin Hererra [États-Unis] ; Erine Raybon Rojas [États-Unis] ; Vartika Singh [Inde] ; Ankit Sakhuja [États-Unis] ; Mark Meersman [États-Unis] ; Drew Dalton [États-Unis] ; Shravan Kethireddy [États-Unis] ; Rahul Nanchal [États-Unis] ; Achuta Kumar Guddati [États-Unis] | Predictors and outcomes of healthcare-associated infections in COVID-19 patients. |
| 000267 (2021) |
Raymond Chee Seong Seet [Singapour] ; Amy May Lin Quek [Singapour] ; Delicia Shu Qin Ooi [Singapour] ; Sharmila Sengupta [Singapour] ; Satish Ramapatna Lakshminarasappa [Singapour] ; Chieh Yang Koo [Singapour] ; Jimmy Bok Yan So [Singapour] ; Boon Cher Goh [Singapour] ; Kwok Seng Loh [Singapour] ; Dale Fisher [Singapour] ; Hock Luen Teoh [Singapour] ; Jie Sun [Singapour] ; Alex R. Cook [Singapour] ; Paul Anantharajah Tambyah [Singapour] ; Mikael Hartman [Singapour] | Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. |
| 000301 (2021) |
Kenneth Sands [États-Unis] ; Richard Wenzel [États-Unis] ; Laura Mclean [États-Unis] ; Kimberly Korwek [États-Unis] ; Jonathon Roach [États-Unis] ; Karla Miller [États-Unis] ; Russell E. Poland [États-Unis] ; L Hayley Burgess [États-Unis] ; Edmund Jackson [États-Unis] ; Jonathan B. Perlin [États-Unis] | No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19. |
| 000324 (2021) |
S. Verheijen [Pays-Bas] ; M. Van Luin [Pays-Bas] ; R J Brüggemann [Pays-Bas] ; Q. De Mast [Pays-Bas] ; R J Hassing [Pays-Bas] ; D M Burger [Pays-Bas] | More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine. |
| 000452 (2021) |
Abdulrhman Mohana [Arabie saoudite] ; Tarek Sulaiman [Arabie saoudite] ; Nagla Mahmoud [Arabie saoudite] ; Mustafa Hassanein [Arabie saoudite] ; Amel Alfaifi [Arabie saoudite] ; Eissa Alenazi [Arabie saoudite] ; Nashwa Radwan [Arabie saoudite] ; Nasser Alkhalifah [Arabie saoudite] ; Ehab Elkady [Arabie saoudite] ; Abdullah Almohaizeie [Arabie saoudite] ; Fouad Abogazalah [Arabie saoudite] ; Khaled Alabdulkareem [Arabie saoudite] ; Fahad Alghofaili [Arabie saoudite] ; Hani Jokdar [Arabie saoudite] ; Fahad Alrabiah [Arabie saoudite] | Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia. |
| 000591 (2021) |
Jonne J. Sikkens [Pays-Bas] ; Didier Collard [Pays-Bas] ; Edgar J G. Peters [Pays-Bas] | Comparison of hospital treatment strategy or of treatment actually received in COVID-19?: Commenting on: Lammers AJJ, Brohet RM, Theunissen REP, Koster C, Rood R, Verhagen DWM, et al. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. Int J Infect Dis. 2020 September. |
| 000593 (2021) |
Min Joo Choi [Corée du Sud] ; Minsun Kang [Corée du Sud] ; So Youn Shin [Corée du Sud] ; Ji Yun Noh [Corée du Sud] ; Hee Jin Cheong [Corée du Sud] ; Woo Joo Kim [Corée du Sud] ; Jaehun Jung [Corée du Sud] ; Joon Young Song [Corée du Sud] | Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study. |
| 000601 (2021) |
Van Thuan Hoang [Viêt Nam] | Comment to Sands et al. - No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19. |
| 000719 (2021) |
Kyungmin Huh [Corée du Sud] ; Wonjun Ji [Corée du Sud] ; Minsun Kang [Corée du Sud] ; Jinwook Hong [Corée du Sud] ; Gi Hwan Bae [Corée du Sud] ; Rugyeom Lee [Corée du Sud] ; Yewon Na [Corée du Sud] ; Jaehun Jung [Corée du Sud] | Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. |
| 000739 (2021) |
Stefano Celotto [Italie] ; Nicola Veronese [Italie] ; Mario Barbagallo [Italie] ; Francesca Ometto [Italie] ; Lee Smith [Royaume-Uni] ; Shahina Pardhan [Royaume-Uni] ; Yvonne Barnett [Royaume-Uni] ; Petre Cristian Ilie [Royaume-Uni] ; P Nar Soysal [Turquie] ; Erik Lagolio [Italie] ; Peter Konstantin Kurotschka [Italie] ; Roberto Tonelli [Italie] ; Jacopo Demurtas [Italie] | An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. |
| 000779 (2021) |
Julian J. Gabor [Allemagne] ; Andrea Kreidenweiss [Allemagne] ; Stefan Weber [Allemagne] ; Moaaz Salama [Allemagne] ; Mihaly Sulyok [Allemagne] ; Zita Sulyok [Allemagne] ; Erik Koehne [Allemagne] ; Meral Esen [Allemagne] ; Benno Kreuels [Allemagne] ; Parichehr Shamsrizi [Allemagne] ; Erwin Biecker [Allemagne] ; Benjamin Mordmüller [Pays-Bas] ; Christoph P. Berg [Allemagne] ; Stefano Fusco [Allemagne] ; Carsten Köhler [Allemagne] ; Stefan Kubicka [Allemagne] ; Jens Leitlein [Allemagne] ; Marylyn Addo [Allemagne] ; Michael Ramharter [Allemagne] ; Matthias Schwab [Allemagne] ; Alfred Lennart Bissinger [Allemagne] ; Thirumalaisamy P. Velavan [Viêt Nam] ; Sanjeev Krishna [Royaume-Uni] ; Peter G. Kremsner [Allemagne] | A call to caution when hydroxychloroquine is given to elderly patients with COVID-19. |
| 000A04 (2020) |
Faizan Mazhar [Italie] ; Muhammad Abdul Hadi [Royaume-Uni] ; Chia Siang Kow [Malaisie] ; Albaraa Mohammed N. Marran [Arabie saoudite] ; Hamid A. Merchant [Royaume-Uni] ; Syed Shahzad Hasan [Royaume-Uni] | Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? |
| 000A41 (2020) |
Samia Arshad [États-Unis] ; Paul Kilgore [États-Unis] ; Zohra S. Chaudhry [États-Unis] ; Gordon Jacobsen [États-Unis] ; Dee Dee Wang [États-Unis] ; Kylie Huitsing [États-Unis] ; Indira Brar [États-Unis] ; George J. Alangaden [États-Unis] ; Mayur S. Ramesh [États-Unis] ; John E. Mckinnon [États-Unis] ; William O'Neill [États-Unis] ; Marcus Zervos [États-Unis] | Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. |
| 000A99 (2020) |
Balakrishnan Sadasivam [Inde] ; Shubham Atal [Inde] ; Avik Ray [Inde] ; Swati Sharma [Inde] | The significance of correct dosing of hydroxychloroquine in clinical trials of COVID-19. |
| 000B25 (2020) |
Amit Malviya [Inde] | The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials. |
| 000E09 (2020) |
J Graham Atkinson [États-Unis] | Problems with the analysis in "Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19". |
